American Society Of Clinical Oncology
Positive Sorafenib Data Lead To Analyst Downgrade, Stock Drop
By Anette Breindl
Tuesday, May 17, 2005
Many a biotechnology company can tell war stories of negative Phase III data, followed by analyst downgrades and a decline in stock price. But Onyx Pharmaceuticals Inc. had what is arguably an even more frustrating tale to tell: positive Phase III data, followed by an analyst downgrade and a decline in stock price. (BioWorld Today)
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5423
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.